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Langberg, Andrew L. Smith, David 6. DeLurgio, Angel R. Leon, The Carlyle Fraser Heart 
Center, Emory University School of Medicine, Atlanta, GA 
BACKGROUND: Several large clinical trials of cardiac resynchronization therapy (CRT) 
have now been completed and demonstrate clinical improvement I” patients with con- 
gestive heart failure (CHF). Despite all the studies now becoming available, only a limited 
number of patients and patient populations have been evaluated. 
METHODS: We retrospectively analyzed the first 500 patients treated with CRT at our 
center from July 1999 to December 2001. Implant criteria included patients with lefl ven- 
tricular dysfunction and ejection fraction 2 35% CHF with severe functional impairment 
of NYHA class II- IV, and symptoms refractory to standard medical therapy. Patients 
included primary implants, upgrades from prior pacemakers, chronic atrial fibrillation 
cases. dual pacemakerldefibrillators, and those who required epicardially placed leads. 
Follow-up was after 6 months of active therapy. 
RESULTS: 
pm-implant active CRT p value 
EF (X) 
NYHA class 
Six min. walk (meters) 
MLWHF score 
QRS duration (ms) 
21.6*7.2 30.0+11.3 <.Ol 
3.1r0.4 2.1*0.7 c.01 
270*89 324;91 c.01 
64.7e22.8 39.5*23.8 <.Oi 
1 EOt31 153+30 - <.Ol 
CONCLUSION: A large volume at a single center demonstrates that biventricular pace- 
makers can be placed in a variety of patients with good overall clinical outcomes. CRT 
should be considered as therapy for patients with CHF who are in normal sinus rhythm, 
who have had a previous pacemaker, who have atrial fibrillation, and those who require 
epicardially placed leads with thoracoscopic guidance. CRT has now become standard 
therapy for patients with severe CHF and a widened QRS at Emory University. 
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Lancaster General Heart Center, Lancaster, PA 
Background: Cardiac resynchronization therapy (CRT) is beneficial in the treatment of 
heart failure associated wth QRS >120 ms and ejection fraction5 35%. Successful CRT 
IS achieved by placing a lead on the lateral free wall of the left ventricle (LV). However, 
diaphragmatic pacing, high thresholds and difficult coronary venous structures can pre- 
vedt optimal lead placement. Percutaneous coronary venous angioplasty (PCVA) may 
facilitate LV lead placement in these cases. 
Methods: A retrospective analysis was performed on 35 of 427 patients undergoing CRT 
in whom PCVA was utilized to dilate a target vein for LV lead placement. 
Results: Twenty nine patients had prior open heart surgery. PCVA was performed for 
the following: target vein stenosis (21). target vein clmm (2), obstructive thrombus (2), 
tortuous vein (6), collaterals to provide an alternative location witin the target vein terri- 
tory(4). In one patient both the great cardiac vein and a target vein stenosis required 
PCVA. Non compliant balloons ranging from 2.5-4 mm in diameter and15 to 23mm in 
length were inflated to a maximum of 26 atmospheres. PCVA facilitated lead placement 
in 24 of 35 patients. Analysis of the 11 failures by catgoty revealed: Stenot~c veins 3/21 
did not open at 18 to 22 atmospheres, 2/21 the style& driven lead caught in the disruped 
vein. Tortuous target 416 vein segments recoiled. Small target 212 veins occluded. 
There were no complications associated with PCVA. 
Conclusion: The overall PCVA swcess was 69%. Failures were more common in tortu- 
ous vein segments (67%) and small target veins (100%). Straightening toltwws vessels 
with an auxiliaty indwelling wire may be preferable to PCVA. For the stenotic vein failures 
a cutting balloon may be useful in the 3 cases that does not dilate with a standard balloon 
while an over the wire lead may have worked where the stylete driven lead failed post 
PCVA. Target vein collaterals may be dilated to provide an lead location not otherwise 
available. PCVA safely increases the swcsss of CRT in patients wtth and without prior 
OHS. 
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1139-l A Defibrillator With Constant Effectiveness Over 
Impedance 
Joe L. Sullivaq Robert G. Walker, Fred W. Chapman, Willts A. Tacker, lsabelle Banville, 
Medtronic Physio-Control, Redmond, WA 
Background Patient Impedance for external defibrillation ranges from about 30 to 1503 
or more. Peak current values and shock swcess rates for energy-dosed external defibril- 
lation vary with impedance. This study tested a new dosing approach designed to adjust 
energy to provide the same effectiveness for any impedancelethods The effect of 
impedance on the shock success rate of a conventional 15OJ, impedance-compensating, 
biphasic external defibrillator (CTL) was compared to a ‘constant effectiveness,” variable 
energy defibrillator (STUDY). Five anesthetized pigs (28 - 35kg. 36 - 560) were shocked 
with these two devices after 15 seconds of electrically induced ventricular fibrillation. A 
series resistance of 0. 50 or 100) of was added to create a range of impedances repra- 
sentative of clinical use. Shock sequence was randomized. Shock swcess was docu- 
mented and peak current and voltage were measured for each shock. Delivered energy 
was calculated. Changes in efficacy versus impedance for each device were analyzed 
with ANOVA. Results: CTL delivered a fixed energy (*lo%) but STUDY varied signifi- 
cantly (97J - 310J). CTL shock success rate decreased significantly with increasing 
impedance, while STUDY showed no significant change (see figure). Conclusions: 
STUDY IS equally effective over a wide range of impedances. STUDY avoided delivering 
unnecessarily high current shocks to low impedance subjects, reducing injury risk, and 
increased swcess rates for high impedance sub]ects. 
1139-2 Comparison of Patients With and Without Atrial 
Fibrillation After Imolantation of a Dual-Chamber 
Defibrillator Using a Defibrillation Lead With Free- 
Floating Atrial Bipole 
Andreas Schuchert, Dietmar Schmitz, Bernd Lemke. Hans-Jiirgen Bondke. Thomas 
Zerm, Ulrich Wiegand, Andreas Tiroke, Manuel Pav6n, University Hospital Hamburg- 
Eppendoff, Hamburg, Germany, St. Johannis Hospital, Dortmund, Germany 
Background: The implantation of a single-lead defibrillation lead with a free-floating atrial 
bipole can detect the atrial act&y without the need to implant a separate atrial pacing 
lead. A potential limitation is the inappropriate detection of atrial fibrillation (AF). The aim 
of the study was to compare patients with and without spontaneous AF episodes after 
implantation of a defibrillation lead with a free-floating atrial bipole. 
Methods: The study Included 99 patients with an accepted ICD indication who received 
the dual-chamber ICD Deikos A+ (Biotronik) and the single-lead defibrillation lead Kainox 
VDD. The atrial bipole is positioned 15 or 17.cm proximally to the ventricular tip. The ICD 
has a 4tlmes nwra sensitive atrial detection channel. Patients with and without paroxys- 
mal AF were compared with respect to their clinical characteristcs. electrical measure- 
ments, and Incidence of spontaneous ventricular tachycardia and fibrillation (VT/vF). 
Results: During 6 + 5 months follow-up (1296 patient-months) 8 patients had 19 AF epi- 
sodes and 91 patients remained in sinus rhythm (SR). The NYHA class was 1.7 * 0.7 in 
the SR group and 2.3 f 0.8 in the AF group (p<O.O5). The ejction fraction was 38 * 14% 
in the SR group and 25 * 9% in the AF group (p<O.O5). A history of myocardial infarction 
had 54% of the SR group compared to 100% of the AF group (pcO.05). The P-wave 
amplitude was not different at implantation (SR: 4.8 * 1.7 mV. AF: 3.8 * 2.0 mV) and 
after 6 months (SR: 4.6 I 2.0; AF: 3.3 * 2.0 mV). There were no differences for atrial pac- 
ing threshold, atrial pacing impedance, and for the ventricular electrical measurements. 
Twenty-six (29%) patients with SR had 101 VT / VF episodes and 2 (25%) patients with 
AF episodes had 7 VTNF episodes. The ICD detected 18 AF episodes correctly and P- 
wave undersensing occurred in the remaining episode. 
Conclusion: The incidence of paroxysmal AF during 6 months after ICD implantation was 
8% with a new onset of AF in most patients. Patients with spontaneous AF episodes had 
a more advanced heart failure compared to patients with SR. As the P-wave amplitude 
was similar in patients with and without AF, the ICD detected 95% of the AF episodes 
with fast ventncular rates correctly. 
